Related Experiment Video
Updated: Jul 16, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Bridging the treatment gap: improving compliance with lipid-modifying agents and therapeutic lifestyle changes
1Department of Community and Preventive Medicine, University of Rochester Medical Center, NY, USA.
Insights
Improving patient compliance with lifestyle changes and lipid-modifying therapies is crucial for managing abnormal lipid levels and reducing cardiovascular disease mortality. Addressing this treatment gap requires patient education and physician engagement.
Area of Science:
- Cardiology
- Public Health
Background:
- Cardiovascular disease (CVD) poses a significant societal burden, with abnormal lipid levels contributing to increased coronary heart disease (CHD) mortality.
- Inadequate management of lipid levels represents a critical treatment gap, impacting primary and secondary prevention efforts.
Purpose of the Study:
- To highlight the importance of patient compliance in lipid management for reducing cardiovascular mortality.
- To identify strategies for improving adherence to therapeutic lifestyle changes and lipid-modifying therapies.
Main Methods:
- Literature review and synthesis of current understanding regarding patient compliance in lipid management.
- Analysis of factors contributing to poor adherence and potential interventions.
Main Results:
- Poor patient compliance with lifestyle modifications and lipid-lowering medications is a primary driver of suboptimal lipid management.
- Effective strategies include patient education, physician proactivity, and the use of well-tolerated, convenient therapies.
Conclusions:
- Improving compliance is essential to translate clinical trial benefits of lipid management to the general population and reduce CHD mortality.
- A proactive, collaborative approach involving patients and physicians, alongside optimized therapeutic options, is key to overcoming this challenge.
Abstract:
Despite the large burden of cardiovascular disease on society, abnormal lipid levels, which are associated with an increase in coronary heart disease mortality, are not being adequately managed in many individuals. Poor patient compliance with therapeutic lifestyle changes and lipid-modifying therapies contribute to this treatment gap. If management of lipid levels is to reduce cardiovascular mortality effectively, poor compliance with treatment needs to be understood and addressed. Educating and motivating patients to understand the need for compliance with continued therapy is an important step for ensuring that the benefits of lipid management cited in clinical trials are translated to the general population. This will require a proactive approach from both patients and physicians. Well-tolerated and effective therapies may also help compliance by reducing the incidence of side effects and the need for complex dosing regimens. Suboptimal treatment of lipid levels is currently limiting the effectiveness of primary and secondary prevention of coronary heart disease; methods for improving compliance should be a key strategy to overcoming this problem.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Coronary Artery Disease IV: Preventive Measures
Cardiomyopathy V: Interprofessional Care
Hypertension IV: Drug Therapy and Lifestyle Modifications
Atherosclerosis III: Management
Peripheral Artery Disease III: Interprofessional Care

